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Abstract
Background: Smoking is Australia’s leading preventable cause of premature mortality and a major contributor to
the national disease burden. If quit rates do not dramatically improve, then smoking will continue to be a major
public health issue for decades to come. Harm-reduction approaches using novel nicotine products like e-cigarettes
as long term replacements for smoking have the potential to improve quit rates. However, little research has
assessed such approaches.
Methods/Design: Design: Three-arm parallel-group pragmatic randomised controlled trial.
Participants: People living in Australia who are at least 18 years old, smoke five or more cigarettes per day and are
willing to try a sample of nicotine products.
Intervention: Participants are randomised to receive standard quit advice and medicinal nicotine (Condition A); quit
or substitute advice and medicinal nicotine (Condition B); or quit or substitute advice and medicinal nicotine and
e-cigarettes (Condition C). Participants choose which (if any) nicotine products to receive to try in a free sample
pack followed by a two to three week free supply of their favourite product(s) and the option to purchase more at
a discounted price. Follow-up surveys will assess nicotine product use and smoking.
Primary outcome: Continuous abstinence for at least 6 months.
Target sample size: 1600 people (Condition A: 340; Condition B: 630; Condition C: 630) provides at least 80 %
power at p = 0.05 to detect a 5 % difference in abstinence rates between each condition.
Discussion: This trial will provide data on tobacco harm-reduction approaches and in particular the use of e-cigarettes
as a replacement for smoking.
Trial registration: Australian and New Zealand Clinical Trials Registry: ACTRN12612001210864. Date of
registration: 15/11/2012.
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Background
Smoking is the largest preventable contributor to Australia’s
disease burden [1]. Progress in reducing tobacco-related
harm has been slow as quit rates have not changed substan-
tially over the past 30 years [2]. New strategies that encour-
age more smokers to quit and improve the current modest
success rate of quit attempts could greatly reduce the na-
tional disease burden [2–5].
On an individual basis, substituting cleaner forms of
nicotine use for cigarettes would substantially reduce
much of the health-related harms of tobacco use [6–8].
If more smokers are able to successfully quit smoking
permanently with long-term nicotine use than without
it, a policy that encourages either quitting or long-term
nicotine substitution could achieve greater population
health gains than the current approach of only promot-
ing nicotine abstinence. This harm reduction strategy is
advocated by the UK Royal College of Physicians [3, 5]
and some tobacco control researchers [7, 9–11].* Correspondence: d.fraser2@uq.edu.au
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Harm reduction is one of the three pillars of Australia’s
National Tobacco Strategy 2012–2018 [12]. However,
there are relatively few harm reduction approaches in-
cluded in the strategy. Importantly, it identifies the need
for research that examines the risks and benefits of al-
ternative nicotine delivery systems, including personal
vaporisers or ‘e-cigarettes’. Internationally, the UK govern-
ment has endorsed nicotine harm reduction and recom-
mends harm-reduction approaches including temporary
or long-term use of licensed nicotine-containing products
in its NICE Guidance on the topic for smokers who are
not able to or do not want to stop using nicotine [13]. The
NICE Guidance provides a summary of the evidence in
support of this harm reduction approach and also identi-
fies a number of important gaps in the evidence including
information on other nicotine delivery systems and the ef-
fect of population-level polices and interventions to sup-
port harm reduction.
The most promising reduced harm substitutes for cig-
arettes are medicinal nicotine products, low toxin
smokeless tobacco and e-cigarettes. In Australia, medi-
cinal nicotine products come in various forms such as
gum, patch, lozenge, inhalator, mouth spray, and dissolv-
able oral strips. These products are approved as short-
term quitting aids [14], are available for sale in general
retail outlets and are considered the least harmful
method of using nicotine. Clinical trials demonstrate
that these products increase quit rates when used as ces-
sation aids [15] but there is less evidence regarding the
effect of encouraging their use for long-term substitution
in addition to quitting.
Personal vaporisers are a heterogeneous category of
nicotine delivery systems. They are all battery-powered
devices in which a nicotine solution is heated allowing
the user to inhale the resulting aerosol. Earlier models of
e-cigarette have relatively small batteries that may be
either disposable or rechargeable. Rechargeable ver-
sions use replaceable pre-filled cartridges. These earl-
ier models typically resemble combustible cigarettes
and are sometimes referred to as ‘cigalikes’. Later
models typically consist of a larger rechargeable bat-
tery and a replaceable atomiser, mouthpiece and a
tank which is filled by the user. Later models often
include features that allow users to adjust voltage,
wattage, and airflow.
In Australia, nicotine for non-therapeutic use is consid-
ered a schedule 7 poison, except when contained in to-
bacco intended for smoking [14]. Sale, possession and use
of a schedule 7 poison without authorisation is illegal in
all states and territories [16]. Nicotine in inhaled prepara-
tions for human therapeutic use (e.g. smoking cessation)
is considered to be a prescription only medicine and must
be listed on the Australian Register of Therapeutic Goods
before being sold. There are currently no e-cigarettes or
nicotine solutions for use in vaporisers listed on the regis-
ter. Possession and use of non-nicotine e-cigarettes is
legal, however sale could contravene tobacco control laws
in some states [16].
There is little information on the effectiveness of
e-cigarettes for smoking cessation. Cross-sectional studies
in countries where e-cigarettes are easy to obtain suggest
that many smokers use them as a complete or partial re-
placement for cigarettes or as a short-medium term quit
aid, similar to medicinal nicotine products [17–19]. In a
controlled trial, e-cigarettes were found to perform simi-
larly to medicinal nicotine products for smoking cessation
[20]. However, a Cochrane review [21] graded the evi-
dence on whether e-cigarettes assist smokers to quit
smoking as low due to the small number of high
quality trials.
This pragmatic randomised controlled trial will fill an
important gap in our understanding of the potential harms
and benefits of a low intensity harm reduction interven-
tion: brief advice encouraging long-term use of existing
forms of medicinal nicotine (mouth spray, inhalator, gum,
lozenge) and e-cigarettes as cigarette substitutes, in
addition to advice on short-term use to quit smoking.
Aim
The primary goal of this study is to rigorously evaluate
the effectiveness of two tobacco harm reduction policy
options compared to the current smoking cessation pol-
icy of recommending short-term use of nicotine prod-
ucts to quit smoking. Specifically, we will determine:
1. If Quit or Substitute policies produce more
ex-smokers than the current policy of encouraging
smokers to quit with medicinal nicotine as a short-
term quitting aid only;
2. If the proportion of ex-smokers who become long-
term users of medicinal nicotine or e-cigarettes
increases under the two Quit or Substitute policies
compared to the current policy.
3. If Quit or Substitute policies have detrimental effects
on quitting by turning would-be quitters into long-
term dual users of medicinal nicotine or e-cigarettes
and cigarettes.
Hypotheses
The proportion of smokers who stop smoking will be
greatest under the policy scenario of Quit or Substitute
with medicinal nicotine or e-cigarettes, followed by Quit
or Substitute with medicinal nicotine and least in the
current policy condition: Quit with medicinal nicotine.
We are also interested to see whether the predicted
benefit is entirely due to increased use when e-cigarettes
are an option, whether the addition of the substitute
model adds extra users (i.e., those who want to quit
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smoking but value the experiences nicotine gives them),
and whether there will be any increased rate of cessation
among those who do use. This will be explored in sub-




Three-arm parallel-group pragmatic randomised con-
trolled trial. Please see Fig. 1 for study design and follow
ups.
Participants
Adults living in Australia who smoke at least five ciga-
rettes per day and are willing to try a sample of nicotine
products.
Inclusion criteria
Smokers at least 18 years old, smoke five or more ciga-
rettes per day, are willing to try nicotine products, have
internet access, have the ability to read and understand
English and are willing to complete online surveys over
one year. These criteria are assessed during an online
screening questionnaire as part of the initial enrolment
process. There is no requirement that the person be
planning to quit smoking.
Exclusion criteria
Participants are excluded if they are pregnant, breast-
feeding, or planning to become pregnant within 12
months, or if they suffer from any of the following con-
ditions: Diabetes mellitus treated with insulin, severe al-
lergies, poorly controlled asthma or other throat or
airway disease, stomach ulcer, kidney or liver disease, ad-
renal gland tumour, overactive thyroid, poorly controlled
high blood pressure, a mental health/psychiatric condi-
tion that is being treated with regular medication, or
stroke, heart attack or severe angina in the previous 2
weeks. Exclusion criteria are assessed by self-report.
Recruitment
Recruitment is restricted to those jurisdictions that con-
firmed supplying nicotine e-cigarettes to participants in
a clinical trial is permitted (Queensland, New South
Wales, Victoria, South Australia, and the Australian
Capital Territory). Recruitment is managed by a market
research company (I-view Social Research). I-view main-
tains a national panel of potential participants who are
recruited by telephone, face-to-face, word-of-mouth, on-
line, general media and leaflet advertisements. If neces-
sary to meet the sample quota, further targeted
advertising in general and social media will allow re-
cruitment of additional participants.
Potential participants receive an email invitation from
I-view to participate in the study. The email contains a
URL link to an online screening questionnaire which as-
sesses the inclusion and exclusion criteria. Eligible par-
ticipants are then presented with a brief summary of the
study and asked to confirm their consent to participate.
Those who consent are directed to the baseline survey
and asked to provide their name and contact details.
Upon completing the screening questionnaire and
baseline survey, participants are automatically rando-
mised to one of three conditions using block randomisa-
tion determined by a computer generated random
number sequence. The three conditions represent the
current policy situation, and the two potential harm-
reduction policy options under examination. Participants
are randomised using the ratios and target sample sizes
outlined below:
 Condition A: Quit with medicinal nicotine (21 %,
n = 340)
 Condition B: Quit or substitute with medicinal
nicotine (39 %, n = 630,)
 Condition C: Quit or substitute with medicinal
nicotine and/or e-cigarettes (39 %, n = 630)
Automatic checks by I-view on the respondents and
manual checks by the researchers will remove ineligible
participants. Participants who respond to the screener
survey more than once, do not provide a name, valid
email address, or other valid contact information (postal
address, phone number) are considered ineligible and re-
moved from the study. Likewise, participants who are
subsequently discovered to fail the exclusion criteria are
ineligible.
Blinding
Participants are not blinded to the intervention they re-
ceive and there is no placebo as all the products are pro-
vided as packaged. However, participants only receive
information relevant to their allocated condition and are
unaware that they have been randomised to a particular
condition of study that is offering a different interven-
tion to other participants. More than one participant per
household can enrol, however participants residing at
the same address as another participant are re-allocated
to the same intervention condition as the first enrolling
participant from that household to avoid contamination
of conditions. Sensitivity analyses will be performed with
these participants included and excluded from the data-
set. The research team will follow strict protocols for
distribution of treatment offers and follow-ups to avoid
bias. Outcome measures of cigarette and nicotine prod-
uct use are collected by the market research company
via online surveys. Telephone calls to participants are
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Fig. 1 Trial schema showing study design and follow-ups
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made by the research team following a standardised
script.
Procedure
After completing the baseline survey online, participants
receive more detailed information about the research
study in hardcopy mailed to their postal address, includ-
ing a description of the products they may select from
for trial use and instructions for use. A factsheet is in-
cluded about the harmfulness of nicotine products com-
pared to cigarettes, and possible adverse effects that can
be experienced when using these products, and what to
do if these occur. Participants in condition A (quit with
medicinal nicotine) are encouraged to quit with the as-
sistance of the nicotine products and advised the recom-
mended duration of use is 8–12 weeks. Participants in
Conditions B and C (quit or substitute) are encouraged
to use the nicotine products as short-term quit aids but
to consider using them as a long-term substitute for cig-
arettes if they are unable to stop using nicotine
altogether. The fact sheet in these conditions also in-
cludes information on the benefits of quitting or substi-
tuting compared to smoking but emphasises complete
cessation as the best option from a health perspective.
The materials also instruct participants in how to obtain
their selected nicotine products for the trial from the
study website.
Experimental products
Two types of nicotine product are offered in the trial,
medicinal nicotine and e-cigarettes. The medicinal nico-
tine products offered to all three conditions include
Nicotinell nicotine gum (mint; 2 mg and 4 mg), Nicabate
mini lozenges (1.5 mg and 4 mg) with Nicorette Cooldrop
lozenges (2 mg and 4 mg) substituted when Nicabate mini
lozenges are unavailable, Nicorette Inhalator (15 mg
cartridges) and Nicorette Quickmist Mouth Spray
(150 mg bottles).
The e-cigarette product - only offered to condition C -
is Vype, a disposable e-cigarette available in two nicotine
strengths (3.0 and 4.5 %), manufactured by Nicoventures
Trading Ltd., with a rechargeable version (Vype Reload)
with replaceable cartridges substituted when Vype dis-
posables are unavailable. Vype e-cigarettes are unfla-
voured and contain nicotine, vegetable glycerin, and
water.
Participants receiving e-cigarettes are instructed that
the products are only supplied to them for their use
while participating in the clinical trial and supply to an-
other person or use beyond the trial dates is not permit-
ted. A wallet-sized card is supplied that confirms the
participant has legally been supplied the e-cigarette as
part of a clinical trial and provides the research team’s
contact details. Participants are also instructed not to
use e-cigarettes anywhere smoking is prohibited.
Products are sent via Australia Post or courier depend-
ing on cost, delivery timeframes, and regulations cover-
ing transport of dangerous goods (i.e., lithium batteries).
Participants are required to sign for all parcels and asked
to return all unused and used packs of the e-cigarettes
via pre-paid pre-addressed postage satchels to the re-
search team for destruction.
Trial of products
Sample pack
Participants can log onto the study website and choose
products to try in a sample pack. Participants in condi-
tions A and B are able to select up to three of the medi-
cinal nicotine products, while those in condition C will
be able to select up to four of the products offered (me-
dicinal nicotine and/or e-cigarettes). They are posted
one to two days’ supply of each product selected.
Initiation pack
After they have sampled their selected products, they are
invited to return to the study website to order one or
two products to receive in an initiation pack which con-
tains an amount of their selected product(s) that should
last approximately two to three weeks. Participants are
also allowed to order the initiation pack directly rather
than first ordering a sample pack, if they already have a
clear preference (e.g., from prior experience of using the
products). They have up to four months after ordering
their sample pack to order product(s) for their initiation
pack. This is to maximise the number likely to use the
products, particularly since our recruitment strategy in-
cludes participants who have no stated interest in
quitting.
Discounted products
Participants are able to purchase products from the
study website for up to seven months after ordering
their initiation pack. The price of the medicinal nicotine
products is set at approximately 50 % of the mean price
of a comparable number of cigarettes or at the lowest
price advertised by discount chemists. The prices of
products also vary in relation to production costs mean-
ing disposable e-cigarettes are more expensive than sim-
pler products. The aim is to mimic as far as possible a
market with price set by a rational government policy
using differential taxation that reflects harmfulness. Par-
ticipants may also purchase products from other retail
outlets, however for e-cigarettes, there is no legal sup-
plier in Australia other than the study website.
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Informed consent
After completing the screening questionnaire partici-
pants are given a brief description of the study and asked
whether they consent to continue. Once they consent
and complete the baseline survey, participants are
posted the full study information and product descrip-
tions. They can then choose whether to log onto the
study website to receive the products. The first time they
log onto the website they are again asked to indicate
they have understood the research study and consent to
continue participating. Participants only receive study
products after providing this second consent, however
they are categorised as enrolled and included in analyses
from the point they were randomised to a condition.
Withdrawals
Participants can withdraw from the study at any time
through an option on the study website or by contacting
the research team directly. The can choose whether their
data is retained.
Sample size
In a general population of Australian smokers, 34 % will
make a quit attempt over a 7 month period [22]. We ex-
pect differential recruitment of those more interested in
quitting, and participation in the trial to stimulate more
quit attempts than in a natural setting. We assume that
approximately 60 % of the sample will take up the prod-
ucts beyond the sample pack, with the proportion of
these making a quit attempt similar to that observed in
clinical trials. The 12 month abstinence rate in a system-
atic review of randomised controlled trials of medicinal
nicotine for quitting was 12 % [15]. Therefore, we expect
an abstinence rate of smokers in condition A of 60 % of
12 %, i.e. 7 %. A sample size of 1600 (NA =340; NB =630;
NC =630) will provide greater than 80 % power to detect
a 5 % difference in abstinence rates at 12 months (1-
tailed test, p < 0.05) between conditions A and B, A and
C, and B and C. The unequal allocation between condi-
tions maximises the statistical power for the total sam-
ple. Testing between conditions B and C will require a
greater sample size than testing between conditions A
and B (or A and C) because the difference in propor-
tions to be tested is 12 % vs 17 % rather than 7 % vs
12 %.
A one-tailed test was chosen as the hypotheses are
unidirectional because both new policies (Conditions B
and C) are departures from the current abstinence only
policy and would require a substantial change in current
Australian policy. This pragmatic trial is only interested
in outcomes in one direction; less conservative and more
difficult to implement policies must produce signifi-
cantly greater quitting than less difficult policies to be
given further consideration. If they produce fewer
quitters, the policy implications will be the same as if
they produced equivalent or inferior results, with no
change in status quo likely to be supported.
Data collection
Baseline measures
Information collected from each participant includes
demographics (date of birth, sex, geographic location,
household composition, education); smoking history
(age started smoking, nicotine dependence measured
with Heaviness of Smoking Index [HSI; time to first
cigarette, cigarettes per day] [23], urges to smoke); quit
attempts (time since last quit attempt, duration of last
attempt); intentions to quit (motivation to quit, current
quit plans, perceived difficulty of quitting); prior nicotine
product use (experience with medicinal nicotine, e-ciga-
rettes, smokeless tobacco, non-cigarette smoked to-
bacco; intention to use nicotine products); knowledge of
harms of nicotine and smoking (causes of harms from cig-
arettes and compared to medicinal nicotine, e-cigarettes,
and smokeless tobacco); and overall health.
Follow ups
Phone call
Ten days after receiving the sample pack, the research
team telephone the participant to identify any problems
and, if participants are unable to be contacted after three
attempts, they are sent an email asking them to confirm
they received the sample pack and offer the opportunity
to ask questions.
Post-sampler survey
When placing their initiation pack order, participants
complete a brief questionnaire on study website about
their experiences with the sample pack and the reasons
behind their product choices for the initiation pack.
Post-initiation pack surveys
Participants are invited by I-view to complete online sur-
veys three weeks, seven months, and one year after or-
dering their initiation pack. They are asked about their
product use, smoking, quit attempts, and adverse effects
that may be related to using the nicotine products.
Participants who do not order an initiation pack are
assigned a dummy initiation pack order date to allow
timing of follow up surveys. If they order a sample pack
then the date of this order is used, while those who
never order a sample pack or initiation pack are
assigned a dummy order date as their baseline survey
completion date. Incentives ($30 gift card) are paid to
participants for completing each of the final two surveys.
I-view Social Research panellists also receive I-view
points for completing surveys, which can be exchanged
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for rewards such as gift cards or charitable donations
and entry into a prize draw.
Primary outcomes
The primary outcome is the percentage in each condi-
tion that have:
1) Continuous abstinence (not smoked for at least
six months) with or without current/recent
medicinal nicotine or e-cigarette use; and
2) Continuous smoking abstinence forat least
six months with no medicinal nicotine or e-cigarette
use for 3 months or more.
Secondary outcomes
The secondary outcomes are:
1) Seven-day point prevalence abstinence measures of
the above primary outcomes;
2) The proportion of each condition concurrently using
medicinal nicotine and cigarettes, the quantity of
each consumed, their interest in quitting smoking,
and interest in eventually quitting all medicinal
nicotine;
3) The proportion of condition C concurrently using
e-cigarettes and cigarettes, the quantity of each
consumed, their interest in quitting smoking, and
interest in eventually quitting all use;
4) The quantity of cigarettes consumed by current
smokers as a function of medicinal nicotine or
e-cigarette use in each condition, and their interest
in quitting smoking;
5) The proportion of each condition that order a
product, what product is ordered, the amount used
over what period; and
6) The proportions that make a quit attempt and
length of all quit attempts made (both from smoking
and all nicotine).
Analytical methods
Participants in the three conditions will be compared on
demographic, smoking history and nicotine dependence
characteristics to confirm successful randomisation. Par-
ticipant outcomes will be analysed on an “intention to
treat” basis [24], i.e. analysed in the condition to which
they were randomly allocated regardless of whether they
actually received any of the allocated intervention, sub-
sequently withdrew from the study, or deviated from the
protocol. Those lost to follow up will be modelled in
various ways including having continued to smoke (the
most conservative assumption). This approach gives
pragmatic estimates of the benefit of a change in policy
under various assumptions, rather than of potential
benefit in participants who receive the intervention
exactly as planned.
The primary outcomes will be analysed with multivari-
able logistic regression to determine the odds ratio for
each outcome measure for Condition B and Condition C
compared to Condition A and for Condition C com-
pared to Condition B. Baseline characteristics (demo-
graphic, smoking history and quit intention variables)
will be included as covariates to adjust for any baseline
differences between the conditions. This will also reduce
the impact of any differences between the sample com-
position and the Australian smoking population. Results
will be reported as the odds ratio for quitting smoking
and the odds ratio for quitting all nicotine use associated
with each of the test policy scenarios compared to the
relevant referent categories (Condition A or B).
Subsidiary analyses will explore quitting as a function of
trying and of time to relapse, and assess whether relapse is
related to cessation of medicinal nicotine/e-cigarettes. Per-
centages (e.g. percentage who quit) will be calculated with
the data weighted to the Australian smoker population
using a nationally representative sample (e.g., NDSHS
[25]). Unweighted data will be used in the regression
analyses.
Ethical considerations
This research study was approved by the Human Research
Ethics Committee of the University of Queensland
(Approval Number 2012001117). Consent is obtained
during the screening survey and again if participants
choose to order nicotine products after receiving the
full study information. All data is stored on a secure
server only accessible to the researchers.
Discussion
This study is designed to provide data on the real-world
effectiveness of harm reduction policies to inform
evidence-based policy decisions. The harm reduction in-
terventions tested in this trial represent a low intensity
intervention targeted at a general population of smokers:
namely brief advice on long-term substitution with nico-
tine as a strategy in addition to using it as a short-term
quit aid along with access to nicotine e-cigarettes. To
have the anticipated effects, the interventions must have
greater efficacy among those who use a product, or must
attract more smokers to use and subsequently try to
quit.
If the trial results indicate that these interventions in-
crease the number of successful quitters in the sample,
they will support the inclusion of harm reduction advice
in general quit smoking messages and potentially greater
access to novel nicotine products, such as e-cigarettes. If
we fail to find the anticipated benefit it will be important
to determine whether this is because of a failure to
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increase product trial and use or if there is no greater effi-
cacy as a consequence of adding the substitution advice
and an e-cigarette option in addition to standard quit ad-
vice. We expect the results of this trial to make a contri-
bution to the debate on whether the current suite of
tobacco control strategies should include harm reduction
policies, and which nicotine products should be included
in such a policy. It will also provide important information
as to whether making harm reduced products available
along with harm reduction advice results in sufficient
numbers take them up for it to affect quit rates.
Our recruitment of participants from a market re-
search company allows a large sample of smokers with
varying baseline levels of interest in quitting to be
approached in an efficient and low cost way. It is im-
portant to recruit smokers with different levels of inter-
est in quitting for this pragmatic trial, as harm reduction
messages may be more relevant to non-treatment seek-
ing smokers than those who are already planning to quit
smoking. Hence, being motivated to quit smoking is not
an eligibility requirement for participation in this trial.
As the intervention is delivered without face-to-face
contact with the participants, we selected an earlier gen-
eration e-cigarette as these require minimal instructions
for use and represent very low risk because the nicotine
liquid is contained within a sealed cartridge in the device
rather than requiring participants to handle refilling
fluids. Furthermore, research suggests that most smokers
who switch to e-cigarettes start with a cigalike-style de-
vice, suggesting these may initially be more attractive
and acceptable to smokers than larger tank style devices
[26]. Due to Australian laws that prohibit the supply of
nicotine as non-therapeutic products [16], we were re-
stricted in what could be used as the trial product. We
selected Vype e-cigarettes for the trial as they met our
requirements for quality assurance over the manufactur-
ing of the device and the liquid contained within it,
which needs to be of medicinal quality. The e-cigarette
market is rapidly evolving with constant improvements
in the technology. Therefore, the product tested in this
trial will not necessarily be representative of e-cigarettes
in general or the most effective e-cigarette on the market
in terms of nicotine delivery.
This study relies on self-report for assessing smoking
abstinence and use of nicotine products. The majority of
data is collected in online surveys delivered via a third
party (I-View). Similarly, trial products are ordered via
the study website and do not require interaction with
the research team unless the participant requires assist-
ance. A follow-up phone call is made early after partici-
pants are sent their ordered products to provide an
opportunity to ask questions, however smoking out-
comes are assessed via the online surveys. The risk of
participants inaccurately reporting smoking abstinence
due to social desirability bias is low due to the minimal
direct contact the participants have with the research
team. Because participants in all conditions received an
intervention any tendency to please the researchers is
likely to be equivalent across conditions. Participants
also receive incentive payments for completing the sur-
veys regardless of whether they quit smoking or not.
Conclusion
Smoking is Australia’s leading preventable cause of pre-
mature mortality and a major contributor to the national
disease burden. It is also a substantial contributor to the
health gap between the least and most disadvantaged
members of society, including Indigenous Australians. If
quit rates do not dramatically improve, then smoking
will continue to be a major public health issue for de-
cades to come. This research will assist national health
policy decision making by examining whether tobacco
harm reduction strategies could accelerate the current
slow rate of decline in smoking prevalence.
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